The Systemic Lupus Activity Measure-Revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a Modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus

Journal of Rheumatology

Volumn 31, Issue 10, 2004, Pages 1934-1940

  Uribe, América G ^a   Vilá, Luis M ^d   McGwin Jr , Gerald ^c   Sanchez, Martha L ^b   Reveille, John D ^a,e   Alarcón, Graciela S ^b,f  

^a Rheumatology ^*

^b Rheumatology   (United States)

^c Kentucky   (United States)

^d UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

^e UNIVERSITY OF TEXAS   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Disease activity; Mexican systemic lupus erythematosus disease activity index; SLEDAI 2K; Systemic lupus activity measure revised; Systemic lupus erythematosus

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DISEASE ACTIVITY; ETHNIC DIFFERENCE; FEASIBILITY STUDY; FEMALE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEXICAN SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX; MODIFIED SLEDAI 2000; OUTPATIENT; PRIORITY JOURNAL; PSYCHOMETRY; PUERTO RICO; RELIABILITY; SYSTEMIC LUPUS ACTIVITY MEASURE REVISED; SYSTEMIC LUPUS ERYTHEMATOSUS; UNITED STATES;

ADULT; ALABAMA; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PUERTO RICO; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SEVERITY OF ILLNESS INDEX; STATISTICS; TEXAS;

EID: 5044238637     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Hayes E, Gordon C, Emery P. Assessment of lupus: where are we now? Ann Rheum Dis 1993;52:169-72.
2. Urowitz MB, Gladman DD. Measures of disease activity and damage in SLE. Baillieres Clin Rheumatol 1998;12:405-13.
3. Liang MH, Stern S, Esdaile JM. Systemic lupus erythematosus activity. An operational definition. Rheum Dis Clin North Am 1988;14:57-66.
4. Liang MH, Fortin PR, Isenberg DA, Snaith L. Quantitative clinical assessment of disease activity in systemic lupus erythematosus: progress report and research agenda. Rheumatol Int 1991;11:133-6.
5. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J Rheumatol 1999;26:490-7.
6. Strand V, Gladman D, Isenberg D, Petri M, Smolen J, Tugwell P. Endpoints: consensus recommendations from OMERACT IV. Lupus 2000;9:322-7.
7. Haq I, Isenberg DA. How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice? Best Pract Res Clin Rheumatol 2002;16:181-94.
8. Hay E, Bacon P, Gordon C. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med 1993;86:447-58.
9. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for disease activity in SLE. Clin Exp Rheumatol 1992;10:541-7.
10. Morimoto C, Sano H, Abe T, Homma M, Steinberg AD. Correlation between clinical activity of systemic lupus erythematosus and the amounts of DNA in DNA/anti-DNA antibody immune complexes. J Immunol 1982;139:1960-5.
11. Bencivelli W, Vitali C, Isenberg DA, et al. Disease activity in systemic lupus erythematosus: report of the Consensus Study Group of the European Workshop for Rheumatology Research. III. Development of a computerized clinical chart and its application to the comparison of different indices of disease activity. The European Consensus Study Group of Disease Activity in SLE. Clin Exp Rheumatol 1992;10:549-54.
12. Petri M, Hellmann D, Hochberg MC. Validity and reliability of lupus activity measures in the routine clinic setting. J Rheumatol 1992;19:53-9.
13. Committee on Prognosis Studies in SLE. Prognosis studies in SLE: an activity index [abstract]. Arthritis Rheum 1986;29 Suppl:S93.
14. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH, and the Committee on Prognosis Studies in SLE. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;35:630-40.
15. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
16. Gladman DD, Goldsmith CH, Urowitz MB, et al. Crosscultural validation and reliability of 3 disease activity indices in systemic lupus erythematosus. J Rheumatol 1992;19:608-11.
17. Gladman DD, Goldsmith CH, Urowitz MB, et al. Sensitivity to change of 3 systemic lupus erythematosus disease activity indices: International validation. J Rheumatol 1994;21:1468-71.
18. Ward MM, Marx AS, Barry NN. Comparison of the validity and sensitivity to change of 5 activity indices in systemic lupus erythematosus. J Rheumatol 2000;27:664-70.
19. Fellows of Harvard College. SLE Activity Measure-Revised (SLAM-R). Revised 1998.
20. Bae S-C, Koh H-K, Chang D-K, Kim M-H, Park J-K, Kim S-Y. Reliability and validity of systemic lupus activity measure-revised (SLAM-R) for measuring clinical disease activity in systemic lupus erythematosus. Lupus 2001;10:405-9.
21. Petri M, Buyon J, Skovron ML, Kim M, for the SELENA Study Group. Reliability of SELENA SLEDAI and flare as clinical trial outcome measures [abstract]. Arthritis Rheum 1998;41 Suppl:S218.
22. FitzGerald JD, Grossman JM. Validity and reliability of retrospective assessment of disease activity and flare in observational cohorts of lupus patients. Lupus 1999;8:638-44.
23. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002;29:288-91.
24. Guzman J, Cardiel MH, Arce-Salinas A, Sánchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 1992;19:1551-8.
25. Alarcon GS, Roseman JM, Bartolucci AA, et al. Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. Arthritis Rheum 1998;41:1173-80.
26. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
27. Hochberg MC, Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematpsus [letter]. Arthritis Rheum 1997;40:1725.
28. Aarden LA, De Groot ER, Feltkamp TEW. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann NY Acad Sci 1975;254:505-15.
29. Bland JM, Airman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
30. Abrahamowicz M, Fortin PR, Du Berger R, Nayak V, Neville C, Liang MH. The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: A decision aid for development of entry criteria for clinical trials. J Rheumatol 1998;25:277-84.
31. Guzman J, Cardiel MH, Arce-Salinas A, Alarcon-Segovia D. The contribution of resting heart rate and routine blood tests to the clinical assessment of disease activity in systemic lupus erythematosus. J Rheumatol 1994;21:1845-4.
32. Rojas-Serrano J, Cardiel MH. Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus 2000;9:601-6.
33. Hernandez-Cruz B, Tapia N, Villa-Romero AR, Reyes E, Cardiel MH. Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico City. Clin Exp Rheumatol 2001;19:395-401.
34. Arce-Salinas A, Cardiel MH, Guzmán J, Alcocer-Varela J. Validity of retrospective disease activity assessment in systemic lupus erythematosus. J Rheumatol 1996;23:846-9.
35. Massardo L, Burgos P, Martinez ME, et al. Antiribosomal P protein antibodies in Chilean SLE patients: no association with renal disease. Lupus 2002;11:379-83.
36. Petri M, Genovese M, Engle E, Hochberg MC. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34:937-44.
37. Walz LeBlanc BAE, Gladman DD, Urowitz MB. Serologically active clinically quiescent systemic lupus erythematosus - predictors of clinical flares. J Rheumatol 1994;21:2239-41.
38. Zonana-Nacach A, Salas M, Sánchez ML, Camargo-Coronel A, Bravo-Gatica C, Mintz G. Measurement of clinical activity of systemic lupus erythematosus and laboratory abnormalities: A 12-month prospective study. J Rheumatol 1995;22:45-9.
39. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342-9.
40. Ho A, Barr SG, Magder LS, Petri M. A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2350-7.
41. Fortin PR, Abrahamowicz M, Clarke AE, et al. Do lupus disease activity measures detect clinically important change? J Rheumatol 2000;27:1421-8.
42. Chang E, Abrahamowicz M, Ferland D, Fortin PR, for CaNIOS Investigators. Comparison of the responsiveness of lupus disease activity measures to changes in systemic lupus erythematosus activity relevant to patients and physicians. J Clin Epidemiol 2002;55:488-97.